Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—Aperiomics introduced its Absolute-NGS Pathogen Detection Platform, a package of three next-generation sequencing services for the identification of known and unknown pathogens, whether bacteria, virus, fungus, or parasite. From a single test, Aperiomics’ technology can simultaneously test for all pathogens using an unbiased sequencing and genomic analysis approach.
Bio-Rad Laboratories’ Geenius HIV-1/HIV-2 Supplemental Assay, which received premarket application approval from the FDA, can differentiate circulating antibodies to HIV types 1 and 2 in whole blood, serum, and plasma. The assay offers a three-step procedure that produces onscreen results in 30 minutes with full traceability.
Beckman Coulter Diagnostics has received FDA 510(k) clearance for the Access 25(OH) Vitamin D Total assay. The assay is available for use on the company’s Access 2 and UniCel DxI series of immunoassay systems and provides excellent stability and convenient storage through packaging designed to prevent light-induced reagent degradation.
February—Roche Diagnostics has signed a definitive purchase agreement with AvanSci Bio for all products associated with the high-performance microdissection of slide-mounted tissue sections. The system consists of instrumentation, software, and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis including real-time PCR, microarrays, and sequencing.
February 2014—Alpha-Tec Systems’ Stain Quality Control Slides are designed to ensure the quality, accuracy, and reliability of stain reagents and staining procedures. The slides provide a known positive and negative control that the laboratory can use to limit the batch-to-batch differences in staining procedures and standardize diagnostic criteria.
January 2015—eBioscience, an Affymetrix business that offers a broad spectrum of immunology and oncology research reagents, and the Binding Site Group have entered into a multiyear distribution agreement.
January 2015—Quest Diagnostics now offers BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA and BRCA genes.
January 2015—Enzo Life Sciences introduced an LH ELISA Kit for sensitive and rapid detection of luteinizing hormone.
January 2015—Biocept launched its lung cancer liquid biopsy testing, performed at its CLIA-certified, CAP-accredited laboratory. The blood-based biomarker testing for non-small cell lung cancer, along with the previously commercialized breast cancer offering, provides options for health care professionals and researchers for when a tumor biopsy is not available or is unsafe to perform or when additional information is desired.
January 2015—Claritas Genomics and NextCode Health announced a strategic partnership bringing together pediatric medicine and sequence analysis. Claritas Genomics, affiliated with Boston Children’s Hospital, is a CLIA-certified clinical laboratory serving the DNA-based diagnostic testing needs of children’s hospitals.
